top of page

Welcome to
SpyGlass Pharma™

At SpyGlass Pharma™, we're innovating at the intersection of Cataract Surgery and Glaucoma/Ocular Hypertension treatment.

Understanding Cataracts and Cataract Surgery


What is a Cataract?

A cataract is a common eye condition where the lens of your eye becomes cloudy, affecting your vision.

Cataract Surgery:
A Clearer View

Cataract Surgery involves replacing the cloudy lens with a clear artificial lens, known as an Intraocular Lens (IOL), to restore clear vision.


Glaucoma and Ocular Hypertension


Glaucoma: More than Just Eye Pressure

Glaucoma is a group of eye conditions that damage the optic nerve, crucial for good vision, often due to high eye pressure.

Treating Glaucoma and Ocular Hypertension

Typical treatments include daily eye drops, laser treatments, or surgical options like drainage devices.


Introducing the SpyGlass Pharma Drug Delivery Platform

The SpyGlass Pharma™ Drug Delivery Platform is designed to provide years of proven medication to lower Intraocular Pressure (IOP) at the time a patient has cataract surgery

The SpyGlass Pharma™ Drug Delivery Platform has not been approved by the FDA

The SpyGlass Pharma™ Drug Delivery Platform consists of a single-piece, hydrophobic acrylic IOL and two drug eluting pads that slide over each haptic and securely attach at the haptic junction. With the drug pads securely attached, the IOL and pads are loaded into a standard IOL injector. The lens is advanced and injected through a sub 2.4 mm incision and implanted directly into the capsular bag. 

The drug pads remain outside the visual axis and continuously elute directly into the aqueous humor, which carries the active drug to targeted tissues. 


During cataract surgery, your doctor will implant a SpyGlass IOL that is uniquely designed to provide both good vision and allow for drug pads to be secured to the haptics of the IOL.  These drug pads have multiple years of IOP-lowering medication in them that will slowly elute a small amount of medication continuously every day.



SpyGlass Drug Delivery Platform is currently being studied in a US FDA clinical trial evaluating safety and efficacy of the SpyGlass platform with bimatoprost.

Bimatoprost is an IOP-lowering therapy that has been FDA approved for over 20 years and has been used by millions of patients around the world to treat their glaucoma or ocular hypertension.

The SpyGlass Drug Delivery Platform is limited by Federal (or United States) law to investigational use.



SpyGlass technology is also being developed to elute other ophthalmic medication for chronic Eye conditions.  

SpyGlass Pharma™ is additionally developing a Platform Extension that is designed to provide additional years of IOP lowering therapy after a patient has had cataract surgery.  

This platform extension is being developed to give patients additional options beyond the initial treatment implanted at the time of Cataract surgery, allowing patients to continue enjoying SpyGlass technology for many years to come. 

bottom of page